Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Pamela J. Cramer net worth and biography

Pamela Cramer Biography and Net Worth

Insider of Rhythm Pharmaceuticals

Ms. Cramer joined Rhythm as Chief Human Resources Officer in July 2021. She brings 20 years of leadership experience in organizational effectiveness, talent development and human resources (HR) transformation with globally diverse life sciences and financial services companies. She joins Rhythm from Foundation Medicine, where she most recently served as Head of People Solutions and was responsible for leading HR delivery for its more than 1700 employees. Prior to that, Ms. Cramer held senior HR positions at Cambridge Associates, PAREXEL International and Epsilon Data Management. Earlier in her career, Ms. Cramer served in a wide range of positions at Bank of America Merrill Lynch and General Electric, where she began her career as a graduate of the Human Resources Leadership Program. She holds an M.B.A. from Georgetown University.

What is Pamela J. Cramer's net worth?: The estimated net worth of Pamela J. Cramer is at least $322,241.04 as of July 26th, 2023. Ms. Cramer owns 8,418 shares of Rhythm Pharmaceuticals stock worth more than $322,241 as of April 28th. This net worth evaluation does not reflect any other investments that Ms. Cramer may own. Learn More about Pamela J. Cramer's net worth.
How old is Pamela J. Cramer?: Ms. Cramer is currently 50 years old. There are 6 older executives and no younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who is 70 years old. Learn More on Pamela J. Cramer's age.
How do I contact Pamela J. Cramer?: The corporate mailing address for Ms. Cramer and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on Pamela J. Cramer's contact information.
Has Pamela J. Cramer been buying or selling shares of Rhythm Pharmaceuticals?: Pamela J. Cramer has not been actively trading shares of Rhythm Pharmaceuticals over the course of the past ninety days. Most recently, Pamela J. Cramer sold 930 shares of the business's stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $17.64, for a transaction totalling $16,405.20. Following the completion of the sale, the insider now directly owns 8,418 shares of the company's stock, valued at $148,493.52. Learn More on Pamela J. Cramer's trading history.
Who are Rhythm Pharmaceuticals' active insiders?: Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Jennifer Lee (EVP), Yann Mazabraud (EVP), Joseph Shulman (Insider), and Hunter Smith (CFO). Learn More on Rhythm Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rhythm Pharmaceuticals?: In the last twelve months, insiders at the sold shares 19 times. They sold a total of 220,913 shares worth more than $9,178,212.80. The most recent insider tranaction occured on April, 2nd when CAO Christopher Paul German sold 368 shares worth more than $15,367.68. Insiders at Rhythm Pharmaceuticals own 4.7% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.
Information on this page was last updated on 4/2/2024.

Pamela J. Cramer Insider Trading History at Rhythm Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/26/2023	Sell	930	$17.64	$16,405.20	8,418
2/9/2023	Sell	834	$27.66	$23,068.44	6,151
8/19/2022	Sell	13,493	$24.83	$335,031.19	2,224
7/27/2022	Sell	901	$11.68	$10,523.68	2,224

Pamela J. Cramer Buying and Selling Activity at Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $38.28

$37.36

$38.89

50 Day Range

MA: $41.60

$38.01

$49.23

2 Week Range

Now: $38.28

$15.50

$52.57

Volume

305,047 shs

Average Volume

473,855 shs

Market Capitalization

$2.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

Pamela Cramer Biography and Net Worth

What is Pamela J. Cramer's net worth?

How old is Pamela J. Cramer?

How do I contact Pamela J. Cramer?

Has Pamela J. Cramer been buying or selling shares of Rhythm Pharmaceuticals?

Who are Rhythm Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Rhythm Pharmaceuticals?